Cover Image
市場調查報告書

C-C趨化素受體類型4 (C-C CKR-4/K5-5/CD194/CCR4):開發平台分析

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 361648
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
C-C趨化素受體類型4 (C-C CKR-4/K5-5/CD194/CCR4):開發平台分析 C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H1 2018
出版日期: 2018年04月17日 內容資訊: 英文 44 Pages
簡介

本報告提供全球各國的C-C趨化素受體類型4 (C-CCKR-4或K5-5或CD194或CCR4)的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊 ,為您概述為以下內容。

目錄

簡介

  • 分析範圍

C-C趨化素受體類型4 (C-C CKR-4/K5-5/CD194/CCR4)的概要

治療藥的開發情形

  • 臨床實驗的各階段
  • 各治療領域
  • 各症狀

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

各企業開發中的治療藥

治療藥的評估

  • 單劑治療藥/並用治療藥的情況
  • 各作用機制
  • 各投藥法
  • 各分子類型

開發治療藥的企業

  • AstraZeneca Plc
  • ChemoCentryx, Inc.
  • Globavir Biosciences, Inc.
  • Kyowa Hakko Kirin
  • 小野藥品工業

藥物簡介

  • ZD-2098
    • 產品概要
    • 作用機制
    • 研究開發 (R&D)的發展情形
  • CCX-6239
  • E-0001163
  • GBV-3019
  • K-777
  • Mogamulizumab
  • 腫瘤、自體免疫疾病用CCR、CXCR拮抗用小分子

開發暫停的產品

開發中止的產品

值得注意的最新趨勢、新聞稿 (共15件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1407TDB

Summary

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor.

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.The molecules developed by companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively.

Report covers products from therapy areas Oncology, Central Nervous System and Immunology which include indications Solid Tumor, T-Cell Lymphomas, Autoimmune Disorders, Breast Cancer, Cutaneous T-Cell Lymphoma, Epithelial Tumor, Gastric Cancer, Hematological Tumor, Mycosis Fungoides, Myelopathy, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Sezary Syndrome, T-Cell Leukemia and Tropical Spastic Paraparesis.

The latest report C-C Chemokine Receptor Type 4 - Pipeline Review, H1 2018, outlays comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
  • The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Overview
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development
  • Affitech A/S
  • Corion Biotech Srl
  • FLX Bio Inc
  • Kyowa Hakko Kirin Co Ltd
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Drug Profiles
  • AT-008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CBChMF-12 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FLX-475 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • mogamulizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Target CCR4 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 11, 2017: Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017
  • Nov 30, 2017: Kyowa Hakko Kirin Submits the Partial Change Approval Application of Mogamulizumab in Japan
  • Nov 28, 2017: Kyowa Hakko Kirin Announces FDA Acceptance for Filing and Priority Review Designation of Mogamulizumab's Biologics License Application
  • Oct 27, 2017: Kyowa Hakko Kirin Announces Marketing Authorization Application for Mogamulizumab Validated by European Medicines Agency
  • Sep 21, 2017: FLX Bio Selects Immuno-Oncology Clinical Candidate
  • Aug 25, 2017: US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the Treatment of Mycosis Fungoides and Sezary Syndrome
  • Jun 30, 2017: Kyowa Hakko Kirin Announces Initiation of Phase 3 Study in Japan of Mogamulizumab in Patients with HTLV-1 Associated Myelopathy
  • Apr 07, 2017: Kyowa Hakko Kirin Announces Positive Results of the Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma
  • Mar 31, 2017: FLX Bio to Present Poster at the American Association of Cancer Research Conference on its Lead Immuno-Oncology Program Targeting CCR4
  • Jun 06, 2016: Kyowa Hakko Kirin Announces Preliminary Results from Pivotal Phase 2 Study of Mogamulizumab (KW-0761) in Patients with Relapsed or Refractory Adult T-cell Leukemia-Lymphoma
  • Jul 29, 2015: Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.
  • Dec 18, 2014: Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab
  • Dec 10, 2014: Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab in Advanced Solid Tumors
  • Sep 29, 2014: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study
  • Jun 30, 2014: Reapplication Seeking Approval for Additional Indication for ATL of Mogamulizumab
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Affitech A/S, H1 2018
  • Pipeline by Corion Biotech Srl, H1 2018
  • Pipeline by FLX Bio Inc, H1 2018
  • Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top